Introduction
============

Sildenafil citrate (SLD), chemically known as 1-\[\[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1*H*-pyrazolo\[4,3-*d*\]pyrimidin-5-yl)-4-ethoxyphenyl\]sulfonyl\]-4-methylpiperazine citrate, is a selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5.[@b1-dddt-10-1323] It was approved by the US Food and Drug Administration in 1998 for the oral treatment of erectile dysfunction.[@b2-dddt-10-1323] Recently, it has been used for the treatment of pulmonary arterial hypertension and the enhancement of uteroplacental perfusion in case of fetal growth retardation.[@b3-dddt-10-1323],[@b4-dddt-10-1323] However, the drug suffers from poor oral bioavailability (\~40%) that could be attributed to its low water solubility (3.5 mg/mL) and extensive presystemic metabolism, in addition to absorption hindrance by food, especially fat-rich meals.[@b5-dddt-10-1323]--[@b9-dddt-10-1323] To surpass this problem, researchers have been attracted to the investigation of SLD delivery via other routes of administration. Several SLD formulations avoiding peroral route have been developed, including orally disintegrating and orally dissolving films, intranasal microemulsions, and transdermal nanostructure lipid carriers and solid lipid nanoparticles.[@b10-dddt-10-1323]--[@b14-dddt-10-1323]

Transdermal delivery of drugs via the skin provides a leading alternative to peroral route due to bypassing the presystemic metabolism of drugs, prolonging their effect, and reducing inter- and intrasubject variability.[@b15-dddt-10-1323] A major challenge for transdermal drug delivery is the low permeation across the skin due to the natural barrier function of the stratum corneum (SC).[@b16-dddt-10-1323] Several approaches have been applied to improve skin penetration of drugs, including chemical approaches, that is, the use of penetration enhancers, in addition to physical approaches of iontophoresis and sonophoresis.[@b17-dddt-10-1323],[@b18-dddt-10-1323] Recently, attention has been focused on the use of lipid vesicular formulations for enhancing transdermal drug delivery.

Liposomes, the first generation of vesicular formulations, have been widely used as drug delivery system via several routes. Topical liposomal formulations have gained interest due to their safety, controlled release property, and enhanced clinical efficacy.[@b19-dddt-10-1323] However, higher tendency of conventional liposomes to deposit in the upper layers of the skin rather than to penetrate through the deeper layers to give systemic effect has been previously reported.[@b20-dddt-10-1323] New generations of liposomes have been developed to enhance transdermal drug delivery such as ethosomes and transfersomes.[@b20-dddt-10-1323],[@b21-dddt-10-1323] Transfersomes are flexible and ultradeformable vesicular systems, composed of phospholipids and a single-chain surfactant that acts as an edge activator. The edge activator destabilizes the lipid bilayers, thus imparting ultra-flexibility to the vesicular structure that enhances its squeezing and penetration through the skin.[@b22-dddt-10-1323],[@b23-dddt-10-1323] The utilization of transfersomes as a promising transdermal drug delivery system has been studied by several investigators.[@b24-dddt-10-1323]--[@b26-dddt-10-1323] Due to the practical difficulty of applying vesicular systems on the skin, several studies have further incorporated them into gel bases and patch formulations.[@b27-dddt-10-1323]--[@b29-dddt-10-1323]

A screening study to investigate formulation and processing factors that affect the characteristics of SLD transfersomes has been previously conducted in our laboratory.[@b30-dddt-10-1323] Based on the findings of the aforementioned screening study, the aim of this work is to develop an optimized nanosized SLD transfersomal transdermal film with enhanced drug delivery through the skin to the systemic circulation and improved bioavailability. Central composite design (CCD) was applied for the optimization of SLD transfersomes. The optimized transdermal nano-transfersomal film was subjected to ex vivo permeation studies using abdominal rat skin. Furthermore, in vivo pharmacokinetic study was conducted in rats to assess the bioavailability of SLD from the films.

Materials
=========

SLD, Span 80, Span 60, and hydroxypropyl methyl cellulose (HPMC), molecular weight (MW) 86,000 and viscosity 4,000 cP, were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). [l]{.smallcaps}-α-Phosphatidylcholine (soy-95%), MW 775.04, was purchased from Avanti Polar Lipids (Alabaster, AL, USA). High-performance liquid chromatography (HPLC) grade methanol and acetonitrile were obtained from Merck (Darmstadt, Germany). All other reagents and chemicals were of analytical grade. Double-distilled water was used throughout the experiments.

Methods
=======

Preparation of SLD nano-transfersomes
-------------------------------------

Modified lipid film hydration technique was used to prepare SLD nano-transfersomes.[@b30-dddt-10-1323] Briefly, specified amount of the drug, [l]{.smallcaps}-α-phosphatidylcholine, and the edge activator (surfactant) were dissolved in methanol. The mixture was sonicated for 5 minutes in a water bath ultrasonicator (QS3, model F 0023902; Ultrawave Ltd, Cardiff, UK). Rotary evaporation of the solution was then conducted using a Buchi Rotavapor (R-200; BÜCHI Labortechnik AG, Flawil, Switzerland) at a temperature of 45°C under reduced pressure for the removal of excess methanol. The thin film, formed on the flask wall, was kept overnight in a vacuum oven (model 6505; Thermo Fisher Scientific, Waltham, MA, USA) for complete dryness. The dried film was then hydrated with 20 mL phosphate buffer saline (PBS) of specified pH with gentle shaking for 2 hours at room temperature.

Response surface methodology for the optimization of SLD nano-transferosomes
----------------------------------------------------------------------------

Based on the findings of the screening study previously conducted in our laboratory, response surface methodology was applied for the optimization of SLD nano-transfersomes with minimized vesicle size. Specifically, a three-factor three-level CCD was used. Drug-to-phospholipid molar ratio (*X*~1~), surfactant hydrophilic lipophilic balance (HLB) (*X*~2~), and hydration medium pH (*X*~3~) were considered as independent variables. The vesicle size (*Y*) was selected as dependent variable (response). All other formulation and processing variables were kept constant throughout the study. The variables and levels used in the design are presented in [Table 1](#t1-dddt-10-1323){ref-type="table"}. Sixteen experimental runs were prepared including eight (2^3^) fractional factorial points, six axial points to estimate curvature, along with two replicates in the center ([Table 2](#t2-dddt-10-1323){ref-type="table"}). The axial points were located so that their distance from the center of the design space is equal to plus or minus alpha, \|*α*\|. The value of alpha (*α*) was set to 1.682 to achieve a rotatable design (to maintain rotatability, the value of *α* = \[number of factorial runs\]^1/4^ = \[2^3^\]^1/4^ =1.682). Statistical analysis was performed using Design-Expert^®^ Software version 7.0.0 (Stat-Ease Inc., Minneapolis, MN, USA) to assess the effect of the independent variables on the vesicle size (*Y*) as well as the interaction between these variables. To obtain the highest prediction power, three mathematical polynomial models, namely, linear (main effects only), two-factor interaction (effects and interactions), and quadratic models (effects, interactions, and quadratic terms) were evaluated. The equation was then determined according to the model selected to be either: $$Y = \alpha_{0} + \alpha_{1}X_{1} + \alpha_{2}X_{2} + \alpha_{3}X_{3}\mspace{54mu}\left( \text{linear~model} \right)$$ $$\begin{array}{l}
{Y = \alpha_{0} + \alpha_{1}X_{1} + \alpha_{2}X_{2} + \alpha_{3}X_{3}} \\
{\qquad + \alpha_{12}X_{1}X_{2} + \alpha_{13}X_{1}X_{3}} \\
{\qquad + \alpha_{23}X_{2}X_{3}\mspace{72mu}\left( {\text{two} - \text{factor~interaction}} \right)} \\
\end{array}$$ $$\begin{array}{l}
{Y = \alpha_{0} + \alpha_{1}X_{1} + \alpha_{2}X_{2} + \alpha_{12}X_{1} + X_{2}} \\
{\qquad + \alpha_{13}X_{1}X_{3} + \alpha_{23}X_{2}X_{3} + \alpha_{11}X_{1}{}^{2}} \\
{\qquad + \alpha_{22}X_{2}{}^{2}\alpha_{33}X_{3}{}^{3}\mspace{72mu}\left( \text{quadratic~model} \right)} \\
\end{array}$$where *Y* is the measured response; *α*~0~ is a constant representing the arithmetic mean of the response of the 16 formulations; *α*~1~, *α*~2~, and *α*~3~ are the estimated linear coefficients of the factors *X*~1~, *X*~2~, and *X*~3~, respectively, that are related to the magnitude of the effect of these variables on the response; *α*~12~, *α*~13~, and *α*~23~ are the interaction coefficients between each two factors; and *α*~11~, *α*~22~, and *α*~33~ are their quadratic coefficients.[@b26-dddt-10-1323] A synergistic effect on the response is indicated by a positive sign of the coefficient, while an antagonistic effect is indicated by a negative sign.[@b31-dddt-10-1323] The level of statistical significance was set at *P*≤0.05. Numerical optimization method following desirability approach was applied to determine the composition of the optimized SLD nano-transfersomal formulation with minimized vesicular size. The observed and predicted values for the vesicle size of the optimized formulation were statistically compared.

Entrapment efficiency
---------------------

The entrapment efficiency percent (EE%) of SLD nano-transfersomes was determined using indirect centrifugation method. The nano-transfersomal dispersions were centrifuged at 18,000 rpm for 1 hour at 4°C (Sigma Laboratory Centrifuge, Model 3K30, Osterode, Germany) to separate the free unentrapped drug from the vesicles. The supernatant was then filtered through a membrane filter (0.1 µm; EMD Millipore). Aliquots of the filtered supernatant were appropriately diluted, and the concentration of the unentrapped drug was determined using validated HPLC method of assay described later. The % SLD entrapped in the nanotransfersomes was calculated using the following equation: $$\text{EE}\% = \frac{C_{1} - C_{2}}{C_{1}} \times 100$$where *C*~1~ represents the initial amount of drug used and *C*~2~ represents the amount of free unentrapped drug in the supernatant.

HPLC analysis of SLD
--------------------

Modified method of Sheu et al[@b32-dddt-10-1323] adapted to our laboratory was applied for the determination of SLD. Agilent 1200 series HPLC system consisting of quaternary pump (HP 1200; Agilent Technologies, Santa Clara, CA, USA) with a photodiode array detector (HP 1200; Agilent Technologies) was used. The analytical column was C18, 250 mm length ×4.6 mm internal diameter, and particle size 5 µm (Phenomenex, Torrance, CA, USA). The mobile phase was prepared by mixing 30 mM potassium dihydrogen phosphate and acetonitrile in the ratio of 55:45, and the pH was adjusted to 6 using 1N sodium hydroxide. In vitro calibration curve was constructed in the range of 10--1,000 ng/mL by using increasing aliquots of SLD stock solution in methanol (1 mg/mL). A 0.1 mL of propyl paraben solution in methanol as an internal standard stock solution (1 mg/mL) was added to the sample. The volume was adjusted with methanol to obtain the final desired concentration, and 20 µL aliquot of this solution was injected into the HPLC system. The flow rate was set at 0.8 mL/min at ambient temperature, and detection was carried out at 290 nm. The assay procedure was validated in terms of linearity, precision, and accuracy (correlation coefficient, *R*=0.998; lower limit of detection =10 ng/mL; lower limit of quantification =40 ng/mL; relative standard deviation for interday and intraday assay \<5%, accuracy =96.60%). Concentrations of SLD in the withdrawn samples were calculated with reference to the calibration curve of drug/internal standard (IS) peak area ratio against the corresponding SLD concentration.

Vesicle size measurements
-------------------------

The mean vesicle size of SLD nano-transfersomes dispersions was determined by dynamic light scattering technique using Zetatrac (Microtrac Inc., Montgomeryville, PA, USA). Each measurement was done five times, and the mean vesicle size was calculated.

Transmission electron microscopy
--------------------------------

The vesicular shape and morphology of the optimized SLD nano-transfersomes were studied using transmission electron microscope (100 CX-TEM; JEOL, Tokyo, Japan). A drop of diluted transfersomal dispersion was adsorbed onto a carbon-coated grid and then stained with 2% uranyl acid. The excess solution was removed, and the grid was allowed to dry thoroughly before visualization.

Preparation of SLD nano-transfersomal transdermal films
-------------------------------------------------------

The optimized SLD nano-transfersomes were prepared, characterized for vesicular size, and then incorporated into HPMC transdermal films. Briefly, specified amounts of HPMC (matrix forming polymer) were dispersed in double-distilled water to obtain a final concentration of 2%. Propylene glycol was used as a plasticizer, and dimethyl sulfoxide was used as a penetration enhancer at a concentration of 1% for both. The films' composition and the concentrations used were chosen based on preliminary studies for the film properties, performed according to the results of our previous study.[@b33-dddt-10-1323] Specified amount of optimized SLD nano-transfersomes was added to the casting solution with gentle stirring and then left for 24 hours at 4°C to obtain a clear solution. The formed gel was then poured into 9 cm petri dishes. Petri dishes were then left to dry in an oven at 40°C for complete evaporation of water. The films were then covered with backing membrane (CoTran™; 3M, St Paul, MN, USA) and cut into 1×1 cm square strips (1 cm^2^) of uniform thickness, each contained amount of transfersomes equivalent to 1 mg of drug. The strips were packed in aluminum foil and kept in a desiccator over CaCl~2~ at 25°C until further evaluation.[@b33-dddt-10-1323] Control films loaded with raw SLD powder were prepared using the same procedure and the same composition for comparison.

Ex vivo permeation of SLD from transdermal films
------------------------------------------------

### Permeation study

In vitro release and permeation of SLD from optimized SLD nano-transfersomal films and SLD films were studied using automated Franz diffusion cell apparatus (MicroettePlus; Hanson research, Chatsworth, CA, USA). Full thickness excised abdominal male Wistar rat skin (2.5×2.5 cm) was used as a membrane and carefully freed from any subcutaneous fats and examined using magnifier to assure skin integrity.[@b34-dddt-10-1323] The membrane was mounted between the two chambers of the diffusion cell with the SC facing the donor chamber and the dermis facing the receptor chamber. After equilibration in PBS for 15 minutes at 32°C, film strips were applied in the donor compartment through direct contact to the skin. PBS (pH 7.4) was used as a diffusion medium in the receptor chamber (effective diffusion area of 1.76 cm^2^ and volume of 7 mL). The temperature of the diffusion medium was maintained constant at 32°C±0.5°C, and the agitation rate was set to 400 rpm. Aliquots of 2 mL were automatically withdrawn at time intervals of 0.5, 1, 2, 4, 6, 8, 12, and 24 hours and replaced with fresh PBS to maintain constant volume.[@b14-dddt-10-1323] The withdrawn samples were analyzed using the previously described validated HPLC method.[@b32-dddt-10-1323] All experiments were performed in triplicate.

### Permeation data analysis and kinetic modeling

Permeation parameters, namely, steady-state flux, permeability, and diffusion coefficients, were calculated. Steady-state flux, *J*~ss~ (µg/cm^2^ H), was computed from the slope of the linear portion of the cumulative amount drug permeated per squared cm versus time plot. The permeability coefficient, *P*~c~ (cm/h), was determined by dividing the steady-state flux by the initial dug load.[@b27-dddt-10-1323] Diffusion coefficient (*D*) was obtained using the following equation: $$D = \left( \frac{\text{Slope}}{2C_{d}} \right)^{2} \times \pi$$where *C*~d~ is the initial drug concentration in the donor compartment and the slope is that of the cumulative amount of drug permeated versus square root of time plot.[@b35-dddt-10-1323]

The obtained results from the permeation study were fitted into equations of zero, first, Higuchi, and Korsmeyer--Peppas models to describe the kinetics and mechanism of drug permeation from the films.[@b36-dddt-10-1323]--[@b38-dddt-10-1323] Linearity was determined by linear regression analysis, and the correlation coefficient (*r*) was used for evaluation of the goodness of fit to each model. The release exponent (*n*), calculated according to Korsmeyer--Peppas model, was used to elucidate the drug permeation mechanism.

In vivo evaluation of the optimized SLD nano-transfersomal transdermal film
---------------------------------------------------------------------------

### Study design

In vivo evaluation of the optimized SLD nano-transfersomal transdermal films was performed in male Wistar rats weighing 200--250 g (n=36) in comparison to SLD transdermal films and SLD oral suspension. The study protocol was approved by the local Institutional Review Board for Preclinical & Clinical Research Ethics committee, Faculty of Pharmacy that ensured the care and use of animals according to the EU Directive 2010/63/EU on the protection of animals used for scientific purposes and Guiding Principle in Care and Use of Animals (DHEW publication NIH 80-23). Rats were housed at constant temperature and humidity, and were fasted overnight (with free access to water) prior to starting the experiment. The rats were randomly divided into three groups (A, B, and C), each of 12 rats. All the animals received SLD in a dose of 10 mg/kg,[@b39-dddt-10-1323] as follows: Group A (standard control): oral administration of SLD suspensionGroup B (positive control): transdermal application of SLD films (2.5 cm^2^)Group C (test): transdermal application of optimized SLD nano-transfersomal films (2.5 cm^2^).

The applied films were covered with plain adhesive patches. At predetermined intervals, blood specimens were withdrawn in a heparinized glass capillary tube from the tail vein at predetermined time intervals for 36 hours after drug administration. After centrifugation at 1,000 rpm for 8 minutes, plasma was transferred to sterile polypropylene tubes and stored at −20°C until analysis.

### Preparation and analysis of plasma samples

Plasma samples preparation was performed by the extraction method adopted from Sheu et al.[@b32-dddt-10-1323] One milliliter of plasma sample was spiked with 0.1 mL of propyl paraben solution in methanol as an internal standard stock solution (1 mg/mL) and 0.1 mL of NaOH (1N). The sample was extracted with 3 mL ethyl acetate by vortex mixing for 5 minutes. The mixture was then centrifuged for 10 minutes at 3,000 rpm, and the supernatant was evaporated to dryness. The residue was dissolved in 1 mL of the mobile phase and 20 µL of this solution and injected into the HPLC for analysis using the previously described validated HPLC method.[@b32-dddt-10-1323] For construction of in vivo calibration curve (range of 10--1,000 ng/mL), increasing aliquots of SLD stock solution in methanol (1 mg/mL) were added to aliquots of 1 mL of drug-free plasma at the beginning of the procedure.

### Pharmacokinetic and statistical analysis

Pharmacokinetic parameters, namely, elimination half-life (*K*~e~), maximum plasma concentration (*C*~max~), time to maximum plasma concentration (*T*~max~), and area under plasma concentration--time curve (AUC~0--~*~t~* and AUC~0--∞~) were calculated using Kinetica™ software (version 4; Thermo Fisher Scientific).

Pharmacokinetic data were statistically analyzed using SPSS^®^ software, version 16 (SPSS Inc., Chicago, IL, USA). Two-way analysis of variance (ANOVA) followed by Tukey's honest significant difference multiple comparisons test was performed on *C*~max~ and AUC to assess the significance of the formulation and the subjects effects on the pharmacokinetic parameters. Differences are considered to be significant at *P*\<0.05.

Results
=======

Preparation and optimization of SLD nano-transfersomes
------------------------------------------------------

All SLD nano-transfersomes were prepared using modified lipid film hydration technique. Rotatable CCD was applied for the optimization of SLD nano-transfersomes with maximized entrapment efficiency and minimized vesicular size. Entrapment efficiency and vesicular size of all experimental runs were determined ([Table 2](#t2-dddt-10-1323){ref-type="table"}). All prepared experimental trials showed SLD comparable high EE% ranging from 94.21%±1.33% to 95.46%±1.42%; accordingly, EE% was excluded as a response in the study. On the other hand, the experimental trials exhibited marked variations in the vesicular size ranging from 447±13 nm to 2,979±118 nm. Regression analysis of the measured vesicular size according to different polynomial models was performed ([Table 3](#t3-dddt-10-1323){ref-type="table"}). The best fitting model for the data was found to be quadratic model. The validity of the model was confirmed by the residuals plot of the observed and predicted values of the vesicle size ([Figure 1](#f1-dddt-10-1323){ref-type="fig"}). ANOVA for the vesicle size response according to the quadratic model revealed the statistical significance of the model as depicted in [Table 4](#t4-dddt-10-1323){ref-type="table"} (*P*\<0.05). The mathematical equation describing the model in terms of coded factors was generated as follows: $$\begin{array}{l}
{Y = + 1,928.02 - 44.40X_{1} + 369.99X_{2} + 74.88X_{3}} \\
{\qquad - 121.12X_{1}X_{2} + 105.88X_{1}X_{3} + 36.12X_{2}X_{3}} \\
{\qquad - 433.00X_{1}{}^{2} - 148.92X_{2}{}^{2} - 336.84X_{3}{}^{2}} \\
\end{array}$$

ANOVA revealed significance of the linear term *X*~2~ corresponding to surfactant HLB (*P*=0.073) and the quadratic terms $X_{1}^{2}$ and $X_{3}^{2}$ corresponding to drug:phospholipid molar ratio (*P*=0.0086) and hydration medium pH (*P*=0.0246), respectively. The effect of the independent variables on the vesicle size is illustrated in the three-dimensional surface plots and their corresponding contour plots ([Figure 2](#f2-dddt-10-1323){ref-type="fig"}). The composition of the optimized SLD nano-transfersomes with minimized vesicular size was generated using numerical optimization technique following desirability approach. The optimized formulation was prepared at *X*~1~, *X*~2~, and *X*~3~ levels of 1:2.74 (drug-to-phospholipid molar ratio), 2.08 (surfactant HLB), and 8.05 (hydration medium pH). The observed vesicle size of the optimized formulation (130 nm) was close to the predicted value (134.59 nm) showing no statistical significant difference (*P*\<0.05) and % error of 3.41%, thus confirming the reliability of the optimization process.

Visualization of optimized SLD nano-transfersomes
-------------------------------------------------

Transmission electron microscopy has been utilized for evaluating shape and lamellarity of the optimized SLD nano-transfersomes. The representative photomicrograph ([Figure 3](#f3-dddt-10-1323){ref-type="fig"}) showed unilamellar vesicles with spherical shape.

Ex vivo permeation studies
--------------------------

Mean cumulative percent SLD permeated from both SLD nano-transfersomal films and SLD control films was determined ([Figure 4](#f4-dddt-10-1323){ref-type="fig"}). It was evident that the transfersomal films exhibited significantly higher cumulative percent drug permeated relative to the control films (*P*\<0.05). The optimized transfersomal films showed a controlled gradual release over the study period reaching maximum amount of drug permeated of 1.54 folds compared with the control films. In addition, the computed permeability and diffusion coefficients for the optimized films were 1.25 and 1.57 folds higher compared with the control films, respectively. The permeation parameters of SLD from control and transfersomal films are compiled in [Table 5](#t5-dddt-10-1323){ref-type="table"}.

Kinetic analysis of the permeation data revealed that the permeation of SLD from both optimized SLD nano-transfersomal films and control SLD films followed Higuchi diffusion kinetics as evidenced by the highest correlation coefficient (*R*) of the model ([Table 6](#t6-dddt-10-1323){ref-type="table"}). The (*n*) exponent obtained from the slope of plot of log fraction of drug released at time *t* (*M~t~*/*M*~∞~) versus time indicates that the release mechanism from control SLD films follows Fickian diffusion (*n*\<0.45), while that the release optimized SLD nano-transfersomal films follows non-Fickian diffusion, anamolous transport (0.45\<*n*\<0.89).

In vivo pharmacokinetic studies
-------------------------------

The concentration of SLD spiked in plasma was linearly correlated to the peak area ratios (SLD/internal standard) with a correlation coefficient of 0.996. The assay showed acceptable precision (coefficient of variation % of \<5% and \<8% for the intraday assay and the interday assay, respectively) and accuracy (96.00%). The extraction recovery of SLD from drug-fortified plasma samples ranged from 92.12% to 103.41%. Mean concentrations of SLD in rats' plasma following oral administration of SLD suspension and transdermal application of control SLD films and optimized SLD nano-transfersomal films were determined ([Figure 5](#f5-dddt-10-1323){ref-type="fig"}). The optimized films showed significantly extended drug absorption compared to control films and suspension, reaching its peak plasma concentration after 15 hours. Both films exhibited significantly higher AUC (*P*\<0.05) compared to oral suspension. The optimized SLD nano-transfersomal films exhibited significantly higher *C*~max~ and almost doubled AUC (*P*\<0.05) compared to control SLD films ([Table 7](#t7-dddt-10-1323){ref-type="table"}). Although the oral suspension showed slightly higher *C*~max~ than the optimized transfersomal film, yet this difference was statistically insignificant at the 95% confidence level.

Discussion
==========

Rotatable CCD was used to evaluate the relation among the independent variables, namely, drug-to-phospholipid molar ratio (*X*~1~), surfactant HLB (*X*~2~), and hydration medium pH (*X*~3~) and the vesicle size (*Y*) of the nano-transfersomes as a measured response. The observed high EE% could be explained based on the hydration medium pH range used and the solubility of the drug. SLD is an amphoteric drug that has two dissociation constants, p*K*~a1~ of 7.10 and p*K*~a2~ of 9.84 corresponding to the basic ionization of NH-piperazine and acidic ionization of NH-amide of pyrazolopyrimidine, respectively.[@b40-dddt-10-1323] Thus, SLD exhibits pH-dependent solubility in aqueous solutions with the least solubility at pH values between p*K*~a1~ and p*K*~a2~ owing to the saturation of the neutral species. In a study of the solubility of SLD over a pH range of 3--11, Wang et al[@b41-dddt-10-1323] reported the least solubility values for SLD at pH of 7--9 (0.025--0.040 mg/mL). Therefore, the high EE% of all trials could be attributed to the low solubility of the drug in the hydration medium (pH 7.5--8.5) that favors the entrapment of the drug into the vesicles. Since all trials showed comparable EE% with no marked difference among them, EE% was not considered as a response for analysis.

After fitting the measured vesicular sizes for individual trials into different polynomial equations, the quadratic model was selected for its largest multiple correlation coefficient (*R*^2^) and smallest predicted residual sum of squares compared to other models. The positive sign of the coefficient of the linear term *X*~2~ indicates a positive effect of the surfactant HLB on the response *Y*, that is, as the HLB of the surfactant moves toward hydrophobicity, a significant reduction in vesicle size is observed. The relation between surfactant HLB and vesicle size could be explained based on the reduced surface energy and the limited water uptake into vesicles core associated with increased hydrophobicity and low HLB values of the edge activators. Both effects could lead to the formation of smaller vesicles.[@b42-dddt-10-1323],[@b43-dddt-10-1323]

Ex vivo permeation studies through excised rat abdominal skin were performed to offer an insight on the in vivo performance of the nano-transfersomal transdermal films in comparison with the control films. The enhanced permeation from transfersomal films could be explained based on the combined advantages of transfersomes and nano-particulate systems. Based on the literature, transfersomes have potential ability to penetrate SC barrier and reach deeper dermal tissues into the systemic circulation owing to their flexibility and deformable structure. Moreover, permeation enhancement by transfersomes involves the presence of surfactants that act as edge activator, thus loosening or destabilizing the lipid bilayer of the membrane and consequently serving as a permeation enhancer.[@b42-dddt-10-1323],[@b44-dddt-10-1323] The nanosize of the vesicles contributes to the permeation enhancement effect since the small vesicular size implies a large surface area that increases the contact with the corneocytes and consequently increases the amount of encapsulated drug permeating the skin.[@b14-dddt-10-1323] The higher permeability and diffusion coefficients exhibited by the optimized nano-transfersomal films compared with control films could confirm their potentiality to enhance and control the permeation of SLD through skin with the possible consequence of improving its transdermal delivery, and thus, its bioavailability. The difference in permeation mechanism between the prepared films could suggest that the permeation of SLD from the control films was governed mainly by diffusion through the polymer matrix, while in case of transfersomal films, the permeation of the drug was controlled by coupled diffusion and erosion.[@b37-dddt-10-1323],[@b38-dddt-10-1323] It is worthy to note that the higher observed initial drug permeation from the control films could be attributed to the effect of the penetration enhancer on the free drug available on the film surface; however, a plateau was rapidly reached after 1 hour due to the slow diffusion of the drug from the film matrix.

Further in vivo pharmacokinetic studies were performed in rats to assess the effect of nano-transfersomal films on the bioavailability of SLD. The delayed *T*~max~ exhibited by the optimized SLD nano-transfersomal films could be indicative for controlled and extended drug absorption. This result well correlates with the ex vivo permeation study that confirmed the ability of the nano-transfersomes to control drug permeation. The significantly higher extent of absorption of both films compared to oral suspension could be due to the avoidance of the first-pass effect by the transdermal route of administration. Moreover, the higher extent of absorption demonstrated by the optimized films compared to control films could be attributed to the enhanced permeation characteristics of SLD transfersomes owing to its ultra-flexibility and deformability that aid penetration of the vesicles through the skin layers and into systemic circulation.[@b44-dddt-10-1323] In addition, the small vesicle sizes in the nano range could potentially contribute to the permeation and the consequent bioavailability enhancement due to the increased surface area interacting on a fixed area of the SC.[@b33-dddt-10-1323]

Conclusion
==========

Nano-transfersomal films have been investigated as a possible transdermal drug delivery system for SLD. Response surface methodology, specifically CCD, was applied for the optimization of SLD nano-transfersomes with minimized vesicular size. Surfactant HLB was the most significant formulation factor affecting vesicular size. The optimized SLD nano-transfersomes (1:2.74 drug:PL molar ratio, surfactant HLB of 2.08, and hydration medium pH of 8.05) incorporated into HPMC-based transdermal films showed enhanced and controlled ex vivo permeation profile through excised rat abdominal skin compared to control SLD films. In vivo investigations confirmed the higher bioavailability and extended absorption of the drug from optimized films compared to oral suspensions and control films. Based on the previous results, optimized SLD nano-transfersomal transdermal films could be a potential promising drug delivery system for the drug. The enhanced and extended absorption of SLD from the optimized films provides insight on the possibility of the reduction of dose and frequency of administration of the drug.
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![Residuals plot for the observed and predicted vesicle size of SLD nano-transfersomes prepared according to central composite design.\
**Abbreviation:** SLD, sildenafil citrate.](dddt-10-1323Fig1){#f1-dddt-10-1323}

![Three-dimensional surface plots (**A**) and corresponding contour plots (**B**) showing the effects of the independent variables on the vesicle size (*Y*) response.\
**Notes:** Independent variables are drug: PL molar ratio (*X*~1~), surfactant HLB (*X*~2~), and hydration medium pH (*X*~3~). Two variables are considered at a time and the third one is kept constant at its mid value.\
**Abbreviations:** HLB, hydrophilic lipophilic balance; PL, phospholipid.](dddt-10-1323Fig2){#f2-dddt-10-1323}

![TEM photomicrograph of optimized SLD nano-transfersomes (×10,000).\
**Abbreviations:** TEM, transmission electron microscopy; SLD, sildenafil citrate.](dddt-10-1323Fig3){#f3-dddt-10-1323}

![Mean cumulative percent SLD permeated across excised rat abdominal skin from SLD optimized nano-transfersomal films compared to control films.\
**Abbreviations:** SLD, sildenafil citrate; SD, standard deviation; h, hour.](dddt-10-1323Fig4){#f4-dddt-10-1323}

![Mean SLD plasma concentrations following the oral administration of SLD suspension and the transdermal application of SLD optimized nano-transfersomal and control films.\
**Abbreviations:** SLD, sildenafil citrate; SD, standard deviation; h, hour.](dddt-10-1323Fig5){#f5-dddt-10-1323}

###### 

Variables and levels of the central composite design applied for the optimization of SLD nano-transferosomes

  Independent variables             Levels (actual, coded)                        
  --------------------------------- ------------------------ ----- ----- -------- --------
  *X*~1~ (drug:lipid molar ratio)   1:4                      1:6   1:8   1:9.36   1:2.46
  *X*~2~ (surfactant HLB)           2.1                      3.2   4.3   1.35     5.05
  *X*~3~ (hydration medium pH)      7.5                      8     8.5   7.16     8.84
  **Response**                      **Goal**                                      
                                                                                  
  *Y* (vesicle size, nm)            Minimize                                      

**Abbreviations:** SLD, sildenafil citrate; HLB, hydrophilic lipophilic balance.

###### 

Vesicle size and entrapment efficiency of SLD nano-transfersomes according to the central composite design

  Run   Type   Independent variables   Characterization parameters                      
  ----- ------ ----------------------- ----------------------------- ------ ----------- ------------
  1     F      4                       4.3                           8.5    2,350±73    94.40±2.33
  2     F      4                       4.3                           7.5    1,309±48    94.74±1.67
  3     A      9.36                    3.2                           8      447±13      94.21±1.33
  4     C      6                       3.2                           8      2,290±87    94.46±2.01
  5     A      6                       3.2                           8.84   659±25      95.40±1.66
  6     F      8                       4.3                           8.5    2,979±118   94.36±1.89
  7     F      8                       2.1                           7.5    1,204±39    94.36±0.87
  8     A      6                       1.35                          8      828±37      94.37±2.21
  9     F      4                       2.1                           8.5    735±31      94.34±1.38
  10    F      8                       2.1                           8.5    2,738±82    94.49±2.77
  11    A      6                       3.2                           7.16   1,952±77    95.46±1.42
  12    F      4                       2.1                           7.5    720±29      94.32±0.84
  13    C      6                       3.2                           8      2,082±84    94.98±1.13
  14    A      2.64                    3.2                           8      1,735±73    94.45±1.82
  15    A      6                       5.05                          8      2,446±97    94.44±1.44
  16    F      8                       4.3                           7.5    456±18      95.31±2.08

**Notes:**

Results are presented as mean ± SD, n=5;

response variable for the central composite design;

results are presented as mean ± SD, n=3.

**Abbreviations:** SLD, sildenafil citrate; HLB, hydrophilic lipophilic balance; F, factorial; A, axial; C, center; SD, standard deviation.

###### 

Regression analysis of the measured response (vesicle size) according to different polynomial models

  Model                           SD       *R*^2^   Adjusted *R*^2^   PRESS
  ------------------------------- -------- -------- ----------------- ------------
  Linear                          500.80   0.3960   0.2450            4.740E+006
  Two-factor interaction (2 FI)   556.99   0.4396   0.0660            6.481E+006
  Quadratic                       343.75   0.8977   0.7443            4.373E+006

**Note:** *R*^2^ indicates the multiple correlation coefficient and adjusted *R*^2^ indicates the adjusted multiple correlation coefficient.

**Abbreviations:** SD, standard deviation; PRESS, predicted residual sum of square.

###### 

Analysis of variance (ANOVA) and lack of fit parameters for the vesicle size response according to the quadratic model

  Source            Sum of squares   *df*   Mean square   *F*-value   *P*-value
  ----------------- ---------------- ------ ------------- ----------- -----------------------------------------------------
  Model             4.274E+006       9      4.749E+005    4.02        0.0423[\*](#tfn8-dddt-10-1323){ref-type="table-fn"}
  *X*~1~            26,917.64        1      26,917.64     0.23        0.6500
  *X*~2~            1.869E+006       1      1.869E+006    15.82       0.0073[\*](#tfn8-dddt-10-1323){ref-type="table-fn"}
  *X*~3~            76,569.39        1      76,569.39     0.65        0.4515
  *X*~1~*X*~2~      1.174E+005       1      1.174E+005    0.99        0.3574
  *X*~1~*X*~3~      89,676.13        1      89,676.13     0.76        0.4172
  *X*~2~*X*~3~      10,440.13        1      10,440.13     0.088       0.7763
  $X_{1}^{2}$       1.737E+006       1      1.737E+006    14.70       0.0086[\*](#tfn8-dddt-10-1323){ref-type="table-fn"}
  $X_{2}^{2}$       2.055E+005       1      2.055E+005    1.74        0.2354
  $X_{3}^{2}$       1.051E+006       1      1.051E+006    8.90        0.0246[\*](#tfn8-dddt-10-1323){ref-type="table-fn"}
  Residual          7.090E+005       6      1.182E+005                
  Lack of fit       7.040E+005       5      1.408E+005    28.16       0.1421
  Pure error        5,000.00         1      5,000.00                  
  Corrected total   4.983E+006       15                               

**Notes:**

Significant terms. *X*~1~, *X*~2~, *X*~3~ show the drug to lipid molar ratio, the surfactant HLB, and the hydration medium pH, respectively.

**Abbreviations:** *df*, degrees of freedom; HLB, hydrophilic lipophilic balance.

###### 

Ex vivo permeation parameters of SLD optimized nano-transfersomal and control transdermal films

  Formulation                              *D*~max~ (µg) ± SD   *J*~ss~ (µg/cm^2^ h)   *P*~c~ (cm/h) ×10^−3^   *D* ×10^−3^
  ---------------------------------------- -------------------- ---------------------- ----------------------- -------------
  Control SLD films                        152.87±2.09          0.21010805             0.440216                0.284859
  Optimized SLD nano-transfersomal films   235.89±3.76          0.22114828             0.552871                0.44891

**Note:** *J*~ss~ indicates the steady-state flux.

**Abbreviations:** SLD, sildenafil citrate; *D*~max~, maximum amount of drug permeated; *P*~c~, permeability coefficient; *D*, diffusion coefficient; SD, standard deviation.

###### 

Kinetic analysis of permeation data of SLD optimized nano-transfersomal and control transdermal films

  Formulation                              Correlation coefficient (*R*)   n         Release mechanism              
  ---------------------------------------- ------------------------------- --------- ------------------- ---------- ---------------------
  Control SLD films                        0.700865                        0.72011   0.822014            0.204216   Fickian diffusion
  Optimized SLD nano-transfersomal films   0.862806                        0.8888    0.957981            0.652354   Anomalous transport

**Abbreviation:** SLD, sildenafil citrate.

###### 

In vivo mean pharmacokinetics parameters of optimized SLD nano-transfersomal transdermal films compared to control SLD transdermal films and SLD oral suspension

  PK parameter                                                        SLD suspension   Control SLD films   Optimized SLD nano-transfersomal films
  ------------------------------------------------------------------- ---------------- ------------------- ----------------------------------------
  *K* (h^−1^)[a](#tfn13-dddt-10-1323){ref-type="table-fn"}            0.128±0.024      0.075±0.024         0.086±0.01
  *T*~max~ (h)[b](#tfn14-dddt-10-1323){ref-type="table-fn"}           1.00             4.00                15.00
  *C*~max~ (ng/mL)[a](#tfn13-dddt-10-1323){ref-type="table-fn"}       128.81±19.8      79.91±15.16         114.83±12.82
  AUC~0--36~ (ng h/mL)[a](#tfn13-dddt-10-1323){ref-type="table-fn"}   691.23±128.7     942.55±214.8        2,103.77±247.56
  AUC~0--∞~ (ng h/mL)[a](#tfn13-dddt-10-1323){ref-type="table-fn"}    699.17±132.7     1,023.54±243.59     2,326.65±300.91

**Notes:**

Results are presented as mean ± SD (n=12).

Results are presented as median (n=12). *K* is the elimination half-life, *T*~max~ is the time to maximum plasma concentration, and *C*~max~ is the maximum plasma concentration.

**Abbreviations:** PK, pharmacokinetics; SLD, sildenafil citrate; AUC, area under the curve; SD, standard deviation.
